Editorial-21/09/2026
Antidote to drugs: On the counterfeit medicine racket in Bengaluru, Karnataka
The recent bust of a large counterfeit medicine racket in Bengaluru has exposed a chilling vulnerability in India’s healthcare supply chain: life-saving drugs, including cancer medicines and ICU injections, were being relabelled, repackaged and sold at deep discounts to over 90 hospitals and clinics across Karnataka. While arrests have been made and licences cancelled, the episode underscores systemic gaps in drug regulation, hospital procurement practices and inter-agency coordination that demand urgent, structural reform.
How the racket operated
Discovery and scale
The scam came to light after an incidental raid on August 18, 2026, at an unlicensed farmhouse near Bidadi on Bengaluru’s outskirts, where authorities seized suspected fake and expired medicines worth nearly ₹5 crore, along with injection-filling equipment, counterfeit labels and fake invoices. What began as a routine check quickly unraveled into one of the most serious pharmaceutical frauds in recent years, with investigators suspecting that cheap bulk formulations and expired drugs were being refilled into new vials, relabelled as premium imported brands (including well-known multinational names), and sold at around 50% discount to private hospitals and clinics.
A Special Investigation Team (SIT) comprising police and drug inspectors was formed to trace the wider network. Subsequent raids, including one at Krupa Healthcare near Minerva Circle, led to the arrest of licensed pharmacist Veeresh Kumar Jain, identified as a key node in the distribution chain. Investigators believe more than 15 medical representatives were involved in marketing and supplying these drugs, and that the network had inter-state links, sourcing bulk drugs from Telangana and Himachal Pradesh before repackaging them in Karnataka. The alleged kingpin, R. Prashant, is reported to be in Azerbaijan, prompting discussions of a possible CBI probe.
Modus operandi
The racket’s business model combined simple fraud with sophisticated exploitation of regulatory blind spots:
How the racket operated
Discovery and scale
The scam came to light after an incidental raid on August 18, 2026, at an unlicensed farmhouse near Bidadi on Bengaluru’s outskirts, where authorities seized suspected fake and expired medicines worth nearly ₹5 crore, along with injection-filling equipment, counterfeit labels and fake invoices. What began as a routine check quickly unraveled into one of the most serious pharmaceutical frauds in recent years, with investigators suspecting that cheap bulk formulations and expired drugs were being refilled into new vials, relabelled as premium imported brands (including well-known multinational names), and sold at around 50% discount to private hospitals and clinics.
A Special Investigation Team (SIT) comprising police and drug inspectors was formed to trace the wider network. Subsequent raids, including one at Krupa Healthcare near Minerva Circle, led to the arrest of licensed pharmacist Veeresh Kumar Jain, identified as a key node in the distribution chain. Investigators believe more than 15 medical representatives were involved in marketing and supplying these drugs, and that the network had inter-state links, sourcing bulk drugs from Telangana and Himachal Pradesh before repackaging them in Karnataka. The alleged kingpin, R. Prashant, is reported to be in Azerbaijan, prompting discussions of a possible CBI probe.
Modus operandi
The racket’s business model combined simple fraud with sophisticated exploitation of regulatory blind spots:
- Procurement: Low-cost generic or bulk drugs were purchased from manufacturing hubs outside Karnataka.
- Repurposing: Expired or near-expiry medicines were collected, transferred into new containers, and given fresh expiry dates.
- Rebranding: Using counterfeit labels and packaging material, these were passed off as expensive imported brands, including products associated with major multinational pharmaceutical companies.
- Distribution: A network of medical representatives supplied these to hospitals, clinics and medical stores, often at steep discounts that made them attractive to cost-conscious private providers.
- Documentation: Fake invoices and manipulated batch records helped create a veneer of legitimacy, complicating traceability.
The Karnataka Food Safety and Drugs Administration (FDA) has since cancelled licences of 16 firms and suspended eight others, covering both retail pharmacies and wholesalers, while blocking suspect batches on its portal.
Why this matters: patient safety and public trust
Clinical risks
Counterfeit and substandard medicines are not a victimless crime. For patients in ICUs or undergoing cancer treatment, the stakes are existential:
Why this matters: patient safety and public trust
Clinical risks
Counterfeit and substandard medicines are not a victimless crime. For patients in ICUs or undergoing cancer treatment, the stakes are existential:
- Therapeutic failure: Sub-potent or wrong formulations can lead to treatment failure, disease progression and avoidable deaths.
- Toxicity and adverse reactions: Contaminants, incorrect dosages or degraded compounds can cause severe side effects, organ damage or fatal reactions.
- Time sensitivity: In critical care and oncology, delays or ineffective therapy due to fake drugs can irreversibly worsen outcomes.
India has previously faced global scrutiny over contaminated cough syrups linked to deaths abroad, which dented confidence in “Make in India” pharmaceuticals. The Bengaluru racket shows that the threat is not only from manufacturing defects but also from deliberate fraud within the distribution chain.
Systemic implications
Beyond individual harm, such rackets erode trust in:
Systemic implications
Beyond individual harm, such rackets erode trust in:
- Private healthcare: If hospitals cannot guarantee the authenticity of the drugs they administer, patient confidence in private facilities weakens.
- Regulatory oversight: The ease with which an unlicensed unit operated, sourced materials across states and supplied dozens of hospitals points to weak monitoring and enforcement.
- “Pharmacy of the world” ambition: India supplies a significant share of global generics; recurring quality and authenticity scandals undermine this strategic advantage.
Structural weaknesses the racket exploited
Fragmented regulation and enforcement
Drug regulation in India is formally a state subject, but the supply chain is national and increasingly global. This creates several vulnerabilities:
Fragmented regulation and enforcement
Drug regulation in India is formally a state subject, but the supply chain is national and increasingly global. This creates several vulnerabilities:
- Inter-state coordination gaps: Drugs manufactured in one state, repackaged in another and sold in a third can slip through cracks when state FDA departments do not share real-time data or conduct joint operations.
- Limited inspection capacity: State drug controllers often lack the manpower, technical tools and logistical support to routinely audit every wholesale point, repackaging unit and hospital pharmacy.
- Delayed lab testing: Confirming whether a drug is spurious requires laboratory analysis, which can take weeks; by then, suspect batches may have been consumed or redistributed.
Weak traceability and authentication
India has made progress with barcoding and track-and-trace pilots, but implementation remains uneven:
India has made progress with barcoding and track-and-trace pilots, but implementation remains uneven:
- Incomplete end-to-end tracking: While some formulations are barcoded, full serialization from factory to patient is not universal, especially for high-value injectibles and oncology drugs.
- Hospital procurement opacity: Private hospitals often procure through multiple distributors and spot markets, with limited public disclosure of vendors or batch-wise procurement records.
- Limited use of digital verification: QR-code based verification apps and blockchain pilots exist but are not yet mandatory or widely used by hospitals and patients.
Incentive distortions in the private health market
The demand side also matters:
The demand side also matters:
- Cost pressure on hospitals: In a competitive private healthcare market, there is constant pressure to reduce input costs, making deeply discounted “branded” drugs attractive.
- Information asymmetry: Clinicians may not routinely verify batch numbers or authenticity, assuming that procurement via established channels is safe.
- Weak accountability: When adverse outcomes occur, establishing a causal link to a specific drug batch is difficult, diluting deterrence.
What has been done so far
In the immediate aftermath, authorities have taken several steps:
In the immediate aftermath, authorities have taken several steps:
- Criminal investigation: An SIT is probing the network, tracing financial flows, and hunting the absconding accused.
- Regulatory action: The Karnataka FDA has cancelled or suspended licences of 24 firms and blocked suspect batches on its portal.
- Supply chain review: Investigators are examining inter-state links, including sourcing from Telangana and Himachal Pradesh, and the role of medical representatives.
- Hospital scrutiny: Over 90 hospitals and clinics that may have received these drugs are under review, with batch numbers being cross-checked.
These are necessary but largely reactive measures. They address symptoms more than causes.
What needs to change: an antidote beyond arrests
1. Strengthen regulatory architecture
What needs to change: an antidote beyond arrests
1. Strengthen regulatory architecture
- National drug safety authority: India needs a stronger, adequately funded central mechanism with powers to coordinate inter-state raids, maintain a real-time national database of suspect batches, and mandate recalls.
- Mandatory serialization: Extend and enforce end-to-end track-and-trace (with unique identifiers and QR codes) for all critical formulations, especially injectibles, oncology drugs and high-value brands.
- Risk-based inspections: Prioritize inspections of wholesale distributors, repackaging units and hospital pharmacies in high-risk corridors, using data analytics to flag abnormal procurement patterns.
2. Close inter-state coordination gaps
- Inter-state task forces: Create permanent joint task forces between state FDAs, police, and central agencies (CDSCO, NIA/CBI where needed) to tackle cross-border pharma fraud.
- Shared digital platform: A unified, real-time portal for batch alerts, licence cancellations and suspect distributor lists, accessible to all states and major hospital chains, can prevent “licence shopping” across states.
3. Reform hospital procurement and accountability
- Transparent procurement policies: Private hospitals above a certain size should be mandated to disclose major drug vendors, maintain batch-wise procurement records, and subject them to periodic audit.
- Clinical governance: Hospital accreditation bodies (like NABH) should make drug authentication and batch verification part of mandatory clinical governance protocols.
- Whistleblower protections: Encourage pharmacists, medical representatives and hospital staff to report suspicious procurement practices without fear of retaliation.
4. Leverage technology for authentication
- Patient-facing verification: Promote simple mobile apps that allow patients and caregivers to scan QR codes and verify drug authenticity, batch number and expiry at the point of dispensing.
- Blockchain pilots: Scale up blockchain-based pilots for high-risk drug categories to create tamper-proof records from manufacturer to end-user.
- AI-driven anomaly detection: Use machine learning on procurement and sales data to detect abnormal discounting, sudden vendor changes or batch clustering that may indicate fraud.
5. Enhance penalties and deterrence
- Stricter punishments: Amend drug laws to ensure that large-scale counterfeit drug operations attract stringent penal provisions, including long prison terms and heavy fines proportional to the scale of harm.
- Corporate liability: Hold hospital management and senior procurement officers accountable where willful negligence or complicity is established.
- Asset attachment: Treat large pharma fraud as economic crime, enabling attachment and confiscation of proceeds to fund victim compensation and regulatory strengthening.
6. Build public awareness and participation
- Patient education: Inform patients, especially those with chronic and critical illnesses, to check packaging, batch numbers and use verification tools where available.
- Public dashboards: Maintain public dashboards showing recalled batches, cancelled licences and actions taken, to build trust and enable civic oversight.
Way forward
The Bengaluru counterfeit medicine racket is not an isolated crime but a symptom of deeper structural weaknesses in India’s drug regulatory and healthcare delivery ecosystem. Arrests and licence cancellations are necessary first steps, but the real antidote lies in building a more transparent, technologically enabled and accountable system—from factory to pharmacy to patient. Only then can India credibly claim to be both the “pharmacy of the world” and a safe place for its own citizens to seek treatment.
Download Pdf
The Bengaluru counterfeit medicine racket is not an isolated crime but a symptom of deeper structural weaknesses in India’s drug regulatory and healthcare delivery ecosystem. Arrests and licence cancellations are necessary first steps, but the real antidote lies in building a more transparent, technologically enabled and accountable system—from factory to pharmacy to patient. Only then can India credibly claim to be both the “pharmacy of the world” and a safe place for its own citizens to seek treatment.
